News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,974 Results
Type
Article (54638)
Company Profile (272)
Press Release (630064)
Section
Business (195819)
Career Advice (2825)
Deals (35456)
Drug Delivery (119)
Drug Development (82978)
Employer Resources (168)
FDA (16891)
Job Trends (15897)
News (341530)
Policy (34522)
Tag
Academia (2856)
Alliances (49654)
Alzheimer's disease (1390)
Approvals (16846)
Artificial intelligence (240)
Bankruptcy (354)
Best Places to Work (11916)
Biotechnology (161)
Breast cancer (246)
Cancer (1879)
Cardiovascular disease (152)
Career advice (2374)
CAR-T (145)
Cell therapy (403)
Clinical research (66957)
Collaboration (744)
Compensation (224)
COVID-19 (2810)
C-suite (189)
Data (1721)
Diabetes (243)
Diagnostics (6444)
Earnings (75148)
Employer resources (149)
Events (99067)
Executive appointments (618)
FDA (17876)
Funding (641)
Gene therapy (287)
GLP-1 (769)
Government (4748)
Healthcare (19122)
Infectious disease (2942)
Inflammatory bowel disease (130)
Interviews (522)
IPO (15730)
Job creations (4410)
Job search strategy (1994)
Layoffs (514)
Legal (8161)
Lung cancer (274)
Manufacturing (260)
Medical device (13305)
Medtech (13310)
Mergers & acquisitions (20102)
Metabolic disorders (649)
Neuroscience (1861)
NextGen: Class of 2025 (6945)
Non-profit (4875)
Northern California (2097)
Obesity (359)
Opinion (251)
Patents (179)
People (57753)
Phase I (20761)
Phase II (29282)
Phase III (22254)
Pipeline (822)
Postmarket research (2759)
Preclinical (8405)
Radiopharmaceuticals (240)
Rare diseases (364)
Real estate (6206)
Regulatory (23536)
Research institute (2537)
Resumes & cover letters (432)
Southern California (1877)
Startups (3757)
United States (18527)
Vaccines (726)
Weight loss (269)
Date
Today (207)
Last 7 days (810)
Last 30 days (2792)
Last 365 days (33837)
2025 (5476)
2024 (34618)
2023 (39506)
2022 (50358)
2021 (54986)
2020 (54381)
2019 (48035)
2018 (36865)
2017 (33925)
2016 (33467)
2015 (38107)
2014 (30416)
2013 (25508)
2012 (27393)
2011 (28022)
2010 (25515)
Location
Africa (974)
Arizona (165)
Asia (41850)
Australia (6892)
California (4898)
Canada (1640)
China (414)
Colorado (233)
Connecticut (230)
Europe (93364)
Florida (686)
Georgia (159)
Illinois (475)
Indiana (279)
Maryland (749)
Massachusetts (3473)
Michigan (197)
Minnesota (348)
New Jersey (1340)
New York (1380)
North Carolina (900)
Northern California (2097)
Ohio (168)
Pennsylvania (1033)
South America (1335)
Southern California (1877)
Texas (676)
Utah (163)
Washington State (469)
684,974 Results for "maat pharma sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Autoimmune disease
MaaT Clears Phase III in GVHD, Eyes European Submission By Midyear
MaaT013 in 2022 was put under clinical hold by the FDA, which cited safety and efficacy concerns with the sample-pooling method used to produce the investigational therapy. The hold was lifted in April 2023.
January 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
January 21, 2025
·
4 min read
Press Releases
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
January 9, 2025
·
10 min read
Press Releases
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
December 9, 2024
·
5 min read
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
MaaT Pharma (EURONEXT: MAAT – the “Company”) presented new in vitro data characterizing the metabolites produced by MaaT034 and their impact on immune modulation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
April 8, 2024
·
3 min read
Press Releases
CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
December 9, 2024
·
6 min read
Business
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer.
June 24, 2024
·
4 min read
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies
MaaT Pharma (EURONEXT: MAAT – the “Company”) will present new in vitro data at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place on April 5-10 in San Diego, California.
March 19, 2024
·
3 min read
Press Releases
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
November 26, 2024
·
5 min read
Business
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.
May 7, 2024
·
9 min read
1 of 68,498
Next
